Soleno Therapeutics Lawsuit Over Misleading DCCR Trial Claims
A class action lawsuit alleges Soleno Therapeutics misled investors about safety risks in its DCCR trial, causing financial losses.Summary
The Schall Law Firm has filed a class action lawsuit against Soleno Therapeutics, Inc. (NASDAQ: SLNO), alleging violations of securities laws. The lawsuit concerns statements made between March 26, 2025, and November 4, 2025, claiming Soleno misrepresented safety concerns related to its Phase 3 clinical trial of diazoxide choline extended-release tablets (DCCR). Specifically, the complaint asserts that Soleno downplayed safety risks, leading to a misleadingly positive portrayal of the treatment’s commercial potential. Investors who purchased Soleno securities during the specified “Class Period” are encouraged to contact The Schall Law Firm by May 5, 2026, to discuss their legal options. The firm can be reached at 310-301-3335, through their website www.schallfirm.com, or via email at [email protected]. Investors who do not take action may remain absent members of the class.
(Source：Daily Csr)